Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VIVO Cannabis Inc. VVCIF

VIVO Cannabis Inc is a Canada-based company. It is involved in the production and sale of medical and recreational cannabis and the provision of cannabis-related medical information and services in Canada. The company's operating segment includes Cannabis, Patient Clinics, and Corporate. It generates maximum revenue from the Cannabis segment. The company has a presence across three geographical locations - Canada, Germany, and Australia.


OTCQB:VVCIF - Post by User

Bullboard Posts
Post by Schaffhausenon Jun 20, 2019 9:28am
170 Views
Post# 29843683

Why I bought large position in VIVO at 0.50

Why I bought large position in VIVO at 0.50Seems to me that a few things are in favour of VIVO at these SP levels:

1) Market cap versus revenue is in the top of class

2) Business model is more resilient to cannabis oversupply which has created this oversold situation (ie. pharma focus, international markets, class leading price/kg, and brilliantly timed expansion strategy to reduce low grade produciton costs with airhouses and outsourced supply up to 30%).

3) Super strong balance sheet

4) Market will need to start picking survivors, VIVO will easily be in the cohort of survivors given its careful and well directd startegy.

5) 1-4 above make VIVO a top-of-list near term buyout prospect  as all majors players need to QUICKLY expand there business in all the directions that VIVO has already cultivated (excuse the pun).  They will seek to buy high margin brands, patients, supply contracts, international positioning, formulations, and lower cost production capacity to weather the potential of oncoming oversupply.  No sense in buying straight up growth capacity to strengthen business,  rather, its the retail side that will be driving upcoming acquisition action.


Cheers,

Schaff
Bullboard Posts